**Supplemental table 1**. Baseline demographics and clinical characteristics in patients

with ≥3 prior treatment failures

| | Placebo N=286 | Erenumab 70 mg N=191 | Erenumab 140 mg N=190 |
|---|---|---|---|
| N (%)[a] | 98 (34.3) | 69 (36.1) | 65 (34.2) |
| Age, years | 42.4 (11.5) | 42.8 (11.5) | 44.1 (11.3) |
| Female, n (%)[b] | 72 (73.5) | 62 (89.9) | 59 (90.8) |
| Disease duration, years | 24.8 (13.2) | 24.5 (13.3) | 24.6 (11.9) |
| MMD | 18.6 (4.3) | 18.9 (4.4) | 19.0 (4.7) |
| Use of MSM, n (%) | 90 (91.8) | 62 (89.9) | 60 (92.3) |
| Monthly MSMD | 12.0 (7.1) | 11.0 (7.6) | 12.5 (6.1) |
| Medication Overuse, n (%) | 42 (42.9) | 30 (43.5) | 27 (41.5) |

Data are mean (SD) unless stated otherwise. [a] Percentages represent the number of patients in each prior treatment failure subgroup out of the total patients by treatment subgroup; [b] percentages represent categorical variables compared to the total number of patients in each treatment subgroup by prior treatment failure.
MMD, monthly migraine days; MSM, migraine-specific medication; MSMD, acute migraine-specific medication days; N, number of patients in the analysis set; SD, standard deviation